Monograph
J01MA12 - Levofloxacin |
Propably not porphyrinogenic |
PNP |
Rationale
Mainly excreted unmetabolized. No CYP-interactions.
Chemical description
S-enantiomer of ofloxacin. Quinolone antibiotic only metabolized to a very small extent (<5%) to desmethyllevofloxacin and levofloxacin N-oxide. No CYP-ineractions observed. To be observed: May interfere with screening tests for porphyrins in urine due to overlap in fluorescence emission at 600 nm. See the racemate ofloxacin: South African list: use with extreme caution only. French list: use Metabolic basis..ref 383: safe Thunell:One observation of safe use. See also: Schoenfelt and Mamet. Interference of ofloxacin with determination of urinary porphyrins. Clin Chem 1994, 40; 417-19.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
